Rating History for Boston Scientific (BSX) by Nephron
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 4/23/2026 | Chris Pasquale | Upgrade | Buy (Hold) |
N/A (N/A) |
64.87 (46.91) |
-27.69% | Details |
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 4/23/2026 | Chris Pasquale | Upgrade | Buy (Hold) |
N/A (N/A) |
64.87 (46.91) |
-27.69% | Details |
![]() |
|||||||
![]() |
|||||||